NCT06562946View on ClinicalTrials.gov

The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

January 10, 2025

Conditions
Pharmacokinetics
Interventions
DRUG

Pimicotinib

Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.

Trial Locations (1)

Unknown

The first hospital of Jilin University, Changchun

Sponsors
All Listed Sponsors
lead

Abbisko Therapeutics Co, Ltd

INDUSTRY

NCT06562946 - The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function | Biotech Hunter | Biotech Hunter